Cargando…
How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer
The trimodality approach represented by concurrent chemoradiotherapy followed by surgical resection is a highly effective, but potentially toxic therapy for locally advanced non-small-cell lung cancer (NSCLC). In this review, we discuss the current status of this therapy in patients with mediastinal...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2007
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359947/ https://www.ncbi.nlm.nih.gov/pubmed/17473830 http://dx.doi.org/10.1038/sj.bjc.6603751 |